{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:50Z","timestamp":1782337250098,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:15:12Z","timestamp":1770844512000},"page":"257-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Modern Role of Radiation Therapy in Classic Hodgkin Lymphoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Alexandra D.","family":"Dreyfuss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2026.01.001_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2014.06.010","article-title":"The origins of radiotherapy: discovery of biological effects of X-rays by Freund in 1897, Kienbock\u2019s crucial experiments in 1900, and still it is the dose","volume":"112","author":"Widder","year":"2014","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.01.001_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5347","key":"10.1016\/j.hoc.2026.01.001_bib3","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/bmj.1.5347.1704","article-title":"Cure of Hodgkin\u2019s disease","volume":"1","author":"Easson","year":"1963","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.hoc.2026.01.001_bib4","first-page":"175","article-title":"Radiotherapy in Hodgkin\u2019s lymphoma: which dose and for whom","volume":"6","author":"Boll","year":"2012","journal-title":"Hematology Education Program"},{"issue":"1","key":"10.1016\/j.hoc.2026.01.001_bib5","first-page":"114","article-title":"A study of Hodgkin\u2019s disease treated by irradiation","volume":"79","author":"Peters","year":"1958","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"10.1016\/j.hoc.2026.01.001_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1148\/78.4.553","article-title":"The radical radiotherapy of regionally localized Hodgkin disease","volume":"78","author":"Kaplan","year":"1962","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.hoc.2026.01.001_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/PPO.0b013e31819e30d7","article-title":"Late effects of Hodgkin\u2019s disease and its treatment","volume":"15","author":"Ng","year":"2009","journal-title":"Cancer J"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0360-3016(92)90780-L","article-title":"Analysis of supradiaphragmatic clinical stage I and II Hodgkin\u2019s disease treated with radiation alone","volume":"22","author":"Gospodarowicz","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.hoc.2026.01.001_bib9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.1998.16.3.830","article-title":"Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin\u2019s disease: a meta-analysis of 23 randomized trials involving 3,888 patients; International Hodgkin\u2019s Disease Collaborative Group","volume":"16","author":"Specht","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.01.001_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V59.3.455.455","article-title":"The management of stage I--II Hodgkin\u2019s disease with irradiation alone or combined modality therapy: the Stanford experience","volume":"59","author":"Hoppe","year":"1982","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2026.01.001_bib11","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.01.001_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3324\/haematol.2009.015644","article-title":"Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin\u2019s lymphoma: a systematic review","volume":"95","author":"Herbst","year":"2010","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.hoc.2026.01.001_bib13","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.01.001_bib14","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.01.001_bib15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.hoc.2026.01.001_bib16","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.hoc.2026.01.001_bib17","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin\u2019s lymphoma: a question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib18","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ijrobp.2009.05.012","article-title":"Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study","volume":"75","author":"Weber","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.hoc.2026.01.001_bib19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2026.01.001_bib20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2340\/1651-226X.2025.43177","article-title":"Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000","volume":"64","author":"Chamberlin","year":"2025","journal-title":"Acta Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2026.01.001_bib21","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.01.001_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hoc.2026.01.001_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijrobp.2004.08.048","article-title":"Intensity-modulated radiotherapy for lymphoma involving the mediastinum","volume":"62","author":"Goodman","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.hoc.2026.01.001_bib24","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.hoc.2026.01.001_bib25","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group Guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"31","key":"10.1016\/j.hoc.2026.01.001_bib27","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2026.01.001_bib28","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.hoc.2026.01.001_bib30","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.01.001_bib31","first-page":"CD007110","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma","volume":"4","author":"Blank","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.hoc.2026.01.001_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13935","article-title":"Assessment of radiation doses delivered to organs at risk among patients with early-stage favorable Hodgkin lymphoma treated with contemporary radiation therapy","volume":"3","author":"Pinnix","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.hoc.2026.01.001_bib33","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2021006254","article-title":"Informing radiotherapy decisions in stage I\/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry","volume":"6","author":"Jones","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2026.01.001_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2026.01.001_bib35","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1182\/bloodadvances.2022007363","article-title":"A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome","volume":"6","author":"Chohan","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2026.01.001_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable hodgkin lymphoma (BREACH): a multicenter, Open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.01.001_bib37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable hodgkin lymphoma: final analysis of the randomized German hodgkin study group phase II NIVAHL trial","volume":"41","author":"Brockelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2026.01.001_bib38","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2026.01.001_bib39","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.01.001_bib40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.hoc.2026.01.001_bib41","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.01.001_bib42","first-page":"MS-1","article-title":"NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. Version 2025","year":"2025","journal-title":"NCCN"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1995.13.5.1080","article-title":"Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin\u2019s disease: a preliminary report","volume":"13","author":"Bartlett","year":"1995","journal-title":"J Clin Oncol"},{"issue":"9828","key":"10.1016\/j.hoc.2026.01.001_bib44","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.hoc.2026.01.001_bib45","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2026.01.001_bib46","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2026.01.001_bib47","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2026.01.001_bib48","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.01.001_bib49","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2026.01.001_bib50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0360-3016(97)00352-0","article-title":"Salvage radiotherapy for Hodgkin\u2019s disease following chemotherapy failure","volume":"39","author":"Wirth","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib51","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.ijrobp.2005.05.006","article-title":"Long-term follow-up of salvage radiotherapy in Hodgkin\u2019s lymphoma after chemotherapy failure","volume":"63","author":"Campbell","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.hoc.2026.01.001_bib52","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib53","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","article-title":"Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed hodgkin Lymphoma: 20 years of experience","volume":"97","author":"Rimner","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.hoc.2026.01.001_bib54","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.30482","article-title":"A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed\/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"123","author":"Milgrom","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib55","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2023.02.019","article-title":"Peritransplant radiation therapy in patients with refractory or relapsed hodgkin lymphoma undergoing autologous stem cell transplant: long-term results of a retrospective study of the Fondazione Italiana linfomi","volume":"116","author":"Levis","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.hoc.2026.01.001_bib56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"25","key":"10.1016\/j.hoc.2026.01.001_bib57","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2026.01.001_bib58","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.hoc.2026.01.001_bib59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"10295","key":"10.1016\/j.hoc.2026.01.001_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","article-title":"Contemporary radiotherapy: present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2026.01.001_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1205836","article-title":"Radiation for hematologic malignancies: from cell killing to immune cell priming","volume":"13","author":"Dabaja","year":"2023","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.01.001_bib62","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/cncr.33424","article-title":"Immunotherapy and radiation therapy sequencing: state of the data on timing, efficacy, and safety","volume":"127","author":"Williamson","year":"2021","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.hoc.2026.01.001_bib63","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2024-210689","article-title":"Pembrolizumab and involved-site radiation therapy as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin lymphoma: a prospective multicenter phase II study","volume":"144","author":"Dreyfuss","year":"2024","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.hoc.2026.01.001_bib64","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2026.01.001_bib65","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.01.001_bib66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"issue":"32","key":"10.1016\/j.hoc.2026.01.001_bib67","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.01.001_bib68","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2026.01.001_bib69","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:25:47Z","timestamp":1773955547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0889858826000018"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.01.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Modern Role of Radiation Therapy in Classic Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}